CareDx, Inc 10-Kyear ended 2025-12-31

Executive Summary

CareDx sells transplant diagnostic tests, laboratory kits, software and patient services to transplant centers, laboratories and patients, earning revenue from testing reimbursement, product sales and service fees. It is building a broader transplant-care business around AlloSure and AlloMap, using complementary offerings to deepen transplant-center relationships and improve patient testing adherence. FY2025 revenue grew 14%, with pharmacy and digital services expanding fastest, but testing revenue lagged test volumes because of reimbursement and collection adjustments. The return to a net loss largely reflected the prior year’s litigation benefit rather than a collapse in operations; investors must weigh broader adoption against payer uncertainty and management’s expectation of several more years of losses.

What's Happening in the Business

CareDx’s expansion is becoming less dependent on molecular testing alone. Pharmacy sales and a larger Ottr software customer base drove patient and digital solutions growth, while customer conversions supported sales of next-generation sequencing kits. Management’s coordinated selling strategy aims to make these offerings reinforce one another, improving customer loyalty and lowering acquisition costs. Its software now reaches more than 170 U.S. transplant centers.

The core testing franchise also broadened. HeartCare’s indication expanded to pediatric patients of all ages, including newborns. Clinical evidence remains essential to adoption and reimbursement: a 2025 SHORE analysis found patients positive on both HeartCare tests were ≈6 times more likely to have biopsy-confirmed acute cellular rejection than patients negative on both. Development efforts include AlloSure Plus, which combines molecular results and clinical inputs using artificial intelligence, and tests for stem-cell transplantation and cell therapies.

Reimbursement is the immediate strategic uncertainty. A proposed Medicare coverage revision could impose additional criteria, utilization limits or bundled payments for surveillance testing. Separately, AlloSure Kidney’s Medicare rate fell by $0.000088M to ≈$0.00275M effective 1/1/2026. These changes could weaken revenue per test even if clinicians order more tests.

CareDx is investing in automation and enterprise systems while moving AlloSeq manufacturing from Australia to the United States and Europe. Management believes existing laboratory capacity can meet demand for the next few years, making adoption and reimbursement more immediate constraints than physical capacity.

Key Financial Highlights

FY2025 figures; changes are Y/Y.

• Growth trajectory: Revenue growth slowed from 19% in FY2024, principally as testing growth moderated. Nevertheless, Q4 revenue reached $108M, +25%, showing a stronger finish.
• Testing economics: ≈200,000 tests, +14%, outpaced testing revenue growth. A $3.5M refund reserve and $7.8M less revenue from prior-period tests restrained monetization. Q4 testing revenue grew 23% against 17% volume growth, but included ≈$5M from prior periods, so the improvement was not purely current-period pricing.
• Litigation and operating costs: Litigation expense of $5.71M replaced a $96.3M credit, creating a $102M unfavorable swing. Gross profit increased $31.0M; sales and marketing spending rose $20.7M, while general and administrative expense fell $17.6M, chiefly because stock-based compensation within that category declined.
• Cash versus earnings: Against the reported net loss, OCF included $34.9M of noncash stock-based compensation and $15.0M of depreciation and amortization. Capital expenditures were $5.91M, leaving FCF of $36.1M.
• Capital allocation: Repurchases totaled $87.8M vs $0.522M in FY2024, exceeding FCF. Shares outstanding fell 7.0% to 50.9M after issuance, while cash, cash equivalents and marketable securities declined 23% to $201M. CareDx had no debt, but buybacks reduced its investment and funding cushion.

Risk Assessment

• Reimbursement and revenue estimates: Medicare supplied 46% of testing revenue, and the proposed coverage restrictions, a significant Medicare Advantage payer dispute and collection-dependent revenue estimates could reduce both utilization and realized revenue.
• Litigation exposure: Natera’s appeal could restore liability of up to $96.3M plus interest; CareDx’s separate $44.9M false-advertising jury award remains unrecorded and should not be treated as available funding.
• Adoption and competition: Natera, other molecular-testing providers and established biopsy procedures compete with CareDx, while relatively easy switching and high customer-acquisition costs can prevent test growth from becoming durable profit.
• Operating concentration: All U.S. testing runs through the Brisbane laboratory without a redundant facility or earthquake insurance, and sole-source supplies could make an interruption difficult to resolve quickly.
• Regulatory and compliance exposure: The 2025 reversal of expanded federal oversight of laboratory-developed tests reduced immediate pressure, but future regulation and the continuing Justice Department inquiry into kidney-testing and phlebotomy practices could add costs or restrict operations.

What to Watch

• Testing reimbursement: Watch the Medicare coverage decision, due within 365 days of 7/17/2025, and subsequent testing revenue versus volume. Stable collections would validate adoption; tighter coverage or larger refund adjustments would undermine it.
• Broader transplant-center adoption: Patient and digital solutions grew 31%. Continued pharmacy and Ottr expansion would support cross-selling; slowing adoption would weaken the rationale for a broader transplant platform.
• Funding discipline: Repurchases exceeded FCF despite expected continuing losses. Future filings should show whether cash generation supports investment and capital returns without further substantial liquidity erosion.
• Natera litigation: The reversed patent award remains under appeal. A sustained reversal removes a major contingent exposure; reinstatement would materially reduce CareDx’s financial flexibility.